Literature DB >> 28444126

CImbinator: a web-based tool for drug synergy analysis in small- and large-scale datasets.

Åsmund Flobak1, Miguel Vazquez1,2, Astrid Lægreid1, Alfonso Valencia2.   

Abstract

MOTIVATION: Drug synergies are sought to identify combinations of drugs particularly beneficial. User-friendly software solutions that can assist analysis of large-scale datasets are required.
RESULTS: CImbinator is a web-service that can aid in batch-wise and in-depth analyzes of data from small-scale and large-scale drug combination screens. CImbinator offers to quantify drug combination effects, using both the commonly employed median effect equation, as well as advanced experimental mathematical models describing dose response relationships.
AVAILABILITY AND IMPLEMENTATION: CImbinator is written in Ruby and R. It uses the R package drc for advanced drug response modeling. CImbinator is available at http://cimbinator.bioinfo.cnio.es , the source-code is open and available at https://github.com/Rbbt-Workflows/combination_index . A Docker image is also available at https://hub.docker.com/r/mikisvaz/rbbt-ci_mbinator/ . CONTACT: asmund.flobak@ntnu.no or miguel.vazquez@cnio.es. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
© The Author(s) 2017. Published by Oxford University Press.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28444126      PMCID: PMC5860113          DOI: 10.1093/bioinformatics/btx161

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


1 Introduction

The discovery of growth inhibiting drug synergies is important because they allow for a lower dosage of each drug while preserving effects. Drug synergies can thus be exploited to increase drug treatment responses to levels that are normally limited by the toxicity and side effects of each drug. These properties warrant large drug combination screens to discover new synergies (Axelrod ; Crystal ; Mathews Griner ). While currently available software have typically been devised for small scale experiments, the increase in sizes of drug panels demand software solutions designed to batch-wise analyze large-scale combination screen data. Furthermore, user-friendly designs are required to accommodate both biologists and bioinformaticians studying drug synergy. We here present CImbinator, a software tool that offers substantial advance in assisting assessment of drug response effects and synergies from small and large-scale experiments. CImbinator provides an intuitive user interface to upload data for large datasets from a user-supplied datafile. Data from small datasets can also be entered manually. CImbinator enables the user to quickly orient in a large experimental search space through its display in a single web window of color-coded synergy assessments for all drug combinations describing each dose tested. In-depth details of each combination are easily accessible by selecting the drug combination, including dose–response plots, combination effect plots, combination indices and confidence bands. CImbinator assesses drug combination effects based on the ‘Loewe additivity model’ (Loewe, 1953), which is one of the most popular approaches among mathematical models introduced to analyze drug combination effects. Loewe additivity relates the doses of each drug in a combination that elicit a given effect to the doses of each individual drugthat would be required to achieve the same effect level in either single drug formulation (reviewed in Greco ). We estimate effect levels for any dose based on either the median effect model (Chou, 2010), or based on advanced three or four-parametric dose response relationships. Importantly, our extension of the drug synergy analysis with a stochastic procedure enables CImbinator to estimate confidence intervals for the combination indices. The online application contains sample data and an interactive step-by-step tutorial to ease user experience. The source code is freely available and allows to deploy the web page locally or use the functionalities from the command-line or from Ruby scripts (Fig. 1).
Fig. 1

An intuitive user inter-face presents the drug synergy assessment for each drug combination in a birds eye overview matrix (a), with color-coded bars for each drug combination to allow for a quick evaluation of synergies (green = synergy, yellow = additivity, red = antagonism). Individual drug combination responses can be inspected more closely with dose–response relationships for each single drug and the drug combination (b), including combination indexes as confidence bands. See Supplementary Material and online help-section for further information

An intuitive user inter-face presents the drug synergy assessment for each drug combination in a birds eye overview matrix (a), with color-coded bars for each drug combination to allow for a quick evaluation of synergies (green = synergy, yellow = additivity, red = antagonism). Individual drug combination responses can be inspected more closely with dose–response relationships for each single drug and the drug combination (b), including combination indexes as confidence bands. See Supplementary Material and online help-section for further information

2 Methods and functionality

CImbinator provides: CImbinator provides several approaches to determine dose–response curve parameters: For two drugs the additive effect (i.e. assuming no interaction among the drugs with respect to the measured response) is displayed together with the drug response curve of each drug. When possible, random additive contours are computed by estimating the median effect points from the predictive distribution of the single-drug response fits (95% confidence; for least squares or LL.*). These random additive lines serve as confidence bands for the additive line, and are used to compute the CI value intervals. a batch analysis tool, combined with results presented in a ‘birds eye view’ to facilitate investigations of large datasets quick access to details of drug combination results alternative dose-relationship models (least squares fit, log-logistic LL.2-5 fits) uncertainty estimates for predicted additive responses, based on uncertainties in single drug dose–response relationships export of publication-ready graphics (SVG format) an open source software analysis tool for drug synergy assessment web-server backend methods exposed for programmatic access several example datasets a least squares method as originally proposed by Chou, and used in the commercial software packages CompuSyn and CalcuSyn, and several advanced alternative log-logistic dose–response models (LL.2-LL.5) from the R package drc, which have different assumptions on the shape of the drug response curve and which can potentially provide a better fit when a dose–response relationship cannot be approximated by the median effect equation.

3 Use-cases for CImbinator

To demonstrate some of the capabilities of CImbinator, we have uploaded the publicly available datasets from Miller , Haagensen and Szwajda . See the Supplementary Material for these use-cases.

4 Discussion and conclusion

The exponentially increasing search space of drug combination screens calls for novel software solutions to efficiently identify and characterize drug synergies from experimental data is dearly needed. Currently available software, including Combenefit (Di Veroli ), CompuSyn or Chalice (http://cwr.horizondiscovery.com/) often require either extensive computer skills, particular operating systems, or are designed for low-throughput experiments (see Supplementary Table S1 for a comparison of CImbinator and other tools). We tackle these obstacles by providing a user-friendly open-source online software application that accepts batch-wise input from large experiments and an intuitive user-interface that enables novel analysis approaches to facilitate drug combination screening. Click here for additional data file.
  10 in total

1.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

Authors:  Adam S Crystal; Alice T Shaw; Lecia V Sequist; Luc Friboulet; Matthew J Niederst; Elizabeth L Lockerman; Rosa L Frias; Justin F Gainor; Arnaud Amzallag; Patricia Greninger; Dana Lee; Anuj Kalsy; Maria Gomez-Caraballo; Leila Elamine; Emily Howe; Wooyoung Hur; Eugene Lifshits; Hayley E Robinson; Ryohei Katayama; Anthony C Faber; Mark M Awad; Sridhar Ramaswamy; Mari Mino-Kenudson; A John Iafrate; Cyril H Benes; Jeffrey A Engelman
Journal:  Science       Date:  2014-11-13       Impact factor: 47.728

2.  The problem of synergism and antagonism of combined drugs.

Authors:  S LOEWE
Journal:  Arzneimittelforschung       Date:  1953-06

3.  Drug combination studies and their synergy quantification using the Chou-Talalay method.

Authors:  Ting-Chao Chou
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

Review 4.  The search for synergy: a critical review from a response surface perspective.

Authors:  W R Greco; G Bravo; J C Parsons
Journal:  Pharmacol Rev       Date:  1995-06       Impact factor: 25.468

5.  High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.

Authors:  Lesley A Mathews Griner; Rajarshi Guha; Paul Shinn; Ryan M Young; Jonathan M Keller; Dongbo Liu; Ian S Goldlust; Adam Yasgar; Crystal McKnight; Matthew B Boxer; Damien Y Duveau; Jian-Kang Jiang; Sam Michael; Tim Mierzwa; Wenwei Huang; Martin J Walsh; Bryan T Mott; Paresma Patel; William Leister; David J Maloney; Christopher A Leclair; Ganesha Rai; Ajit Jadhav; Brian D Peyser; Christopher P Austin; Scott E Martin; Anton Simeonov; Marc Ferrer; Louis M Staudt; Craig J Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

6.  Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles.

Authors:  Agnieszka Szwajda; Prson Gautam; Leena Karhinen; Sawan Kumar Jha; Jani Saarela; Sushil Shakyawar; Laura Turunen; Bhagwan Yadav; Jing Tang; Krister Wennerberg; Tero Aittokallio
Journal:  Chem Biol       Date:  2015-07-23

7.  Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets.

Authors:  Martin L Miller; Evan J Molinelli; Jayasree S Nair; Tahir Sheikh; Rita Samy; Xiaohong Jing; Qin He; Anil Korkut; Aimee M Crago; Samuel Singer; Gary K Schwartz; Chris Sander
Journal:  Sci Signal       Date:  2013-09-24       Impact factor: 8.192

8.  The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.

Authors:  E J Haagensen; S Kyle; G S Beale; R J Maxwell; D R Newell
Journal:  Br J Cancer       Date:  2012-03-13       Impact factor: 7.640

9.  Combenefit: an interactive platform for the analysis and visualization of drug combinations.

Authors:  Giovanni Y Di Veroli; Chiara Fornari; Dennis Wang; Séverine Mollard; Jo L Bramhall; Frances M Richards; Duncan I Jodrell
Journal:  Bioinformatics       Date:  2016-04-25       Impact factor: 6.937

10.  Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms.

Authors:  Mark Axelrod; Vicki L Gordon; Mark Conaway; Adel Tarcsafalvi; Daniel J Neitzke; Daniel Gioeli; Michael J Weber
Journal:  Oncotarget       Date:  2013-04
  10 in total
  9 in total

1.  PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer.

Authors:  Andrä Brunner; Aldwin Suryo Rahmanto; Henrik Johansson; Marcela Franco; Johanna Viiliäinen; Mohiuddin Gazi; Oliver Frings; Erik Fredlund; Charles Spruck; Janne Lehtiö; Juha K Rantala; Lars-Gunnar Larsson; Olle Sangfelt
Journal:  Elife       Date:  2020-07-06       Impact factor: 8.140

2.  Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells.

Authors:  Paschalis Athanasiadis; Aleksandr Ianevski; Sigrid S Skånland; Tero Aittokallio
Journal:  Methods Mol Biol       Date:  2022

3.  SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples.

Authors:  Aleksandr Ianevski; Anil K Giri; Tero Aittokallio
Journal:  Nucleic Acids Res       Date:  2022-05-17       Impact factor: 19.160

4.  CDCDB: A large and continuously updated drug combination database.

Authors:  Guy Shtar; Louise Azulay; Omer Nizri; Lior Rokach; Bracha Shapira
Journal:  Sci Data       Date:  2022-06-02       Impact factor: 8.501

Review 5.  Charting the Fragmented Landscape of Drug Synergy.

Authors:  Christian T Meyer; David J Wooten; Carlos F Lopez; Vito Quaranta
Journal:  Trends Pharmacol Sci       Date:  2020-02-26       Impact factor: 14.819

6.  Statistical determination of synergy based on Bliss definition of drugs independence.

Authors:  Eugene Demidenko; Todd W Miller
Journal:  PLoS One       Date:  2019-11-25       Impact factor: 3.240

7.  A high-throughput drug combination screen of targeted small molecule inhibitors in cancer cell lines.

Authors:  Åsmund Flobak; Barbara Niederdorfer; Vu To Nakstad; Liv Thommesen; Geir Klinkenberg; Astrid Lægreid
Journal:  Sci Data       Date:  2019-10-29       Impact factor: 6.444

Review 8.  Predicting and Quantifying Antagonistic Effects of Natural Compounds Given with Chemotherapeutic Agents: Applications for High-Throughput Screening.

Authors:  G Lavender Hackman; Meghan Collins; Xiyuan Lu; Alessia Lodi; John DiGiovanni; Stefano Tiziani
Journal:  Cancers (Basel)       Date:  2020-12-10       Impact factor: 6.575

9.  MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery.

Authors:  David J Wooten; Christian T Meyer; Alexander L R Lubbock; Vito Quaranta; Carlos F Lopez
Journal:  Nat Commun       Date:  2021-07-29       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.